Splitomicin, a SIRT1 Inhibitor, Enhances Hematopoietic Differentiation of Mouse Embryonic Stem Cells
- Author:
Jeong A PARK
1
;
Sangkyu PARK
;
Woo Youn PARK
;
Myung Kwan HAN
;
Younghee LEE
Author Information
- Publication Type:Original Article
- Keywords: Mouse embryonic stem cells; Sirt1; Sirt1 inhibitor; Splitomicin; Hematopoietic differentiation
- MeSH: Animals; Cell Differentiation; Cell Survival; Chromatin Assembly and Disassembly; Gene Expression; Gene Silencing; Histone Deacetylases; Metabolism; Mice; Mouse Embryonic Stem Cells; Niacinamide
- From:International Journal of Stem Cells 2019;12(1):21-30
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND AND OBJECTIVES: Embryonic stem (ES) cells have pluripotent ability to differentiate into multiple tissue lineages. SIRT1 is a class III histone deacetylase which modulates chromatin remodeling, gene silencing, cell survival, metabolism, and development. In this study, we examined the effects of SIRT1 inhibitors on the hematopoietic differentiation of mouse ES cells. METHODS AND RESULTS: Treatment with the SIRT1 inhibitors, nicotinamide and splitomicin, during the hematopoietic differentiation of ES cells enhanced the production of hematopoietic progenitors and slightly up-regulated erythroid and myeloid specific gene expression. Furthermore, treatment with splitomicin increased the percentage of erythroid and myeloid lineage cells. CONCLUSIONS: Application of the SIRT1 inhibitor splitomicin during ES cell differentiation to hematopoietic cells enhanced the yield of specific hematopoietic lineage cells from ES cells. This result suggests that SIRT1 is involved in the regulation of hematopoietic differentiation of specific lineages and that the modulation of the SIRT1 activity can be a strategy to enhance the efficiency of hematopoietic differentiation.
